Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;20(1):6-16.
doi: 10.5056/jnm.2014.20.1.6. Epub 2013 Dec 30.

New and future drug development for gastroesophageal reflux disease

Carla Maradey-Romero  1 , Ronnie Fass  1
Affiliations
Review

New and future drug development for gastroesophageal reflux disease

Carla Maradey-Romero et al. J Neurogastroenterol Motil. 2014 Jan.

Abstract

Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug development for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)'s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist's, extended release PPI's, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies.

Keywords: Erosive esophagitis; Gastroesophageal reflux; Heartburn; Proton pump inhibitors.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Ronnie Fass is a reasearcher for Mederi Therapeutics; speaker for Takeda, Astrazeneca and Eisai; and a consultant for Takeda and Given Imaging.

References

    1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–1920. - PubMed
    1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710–717. - PMC - PubMed
    1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. Published Online First: 13 Jul 2013. gutjnl-2012-304269. - PMC - PubMed
    1. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179–1187. - PMC - PubMed
    1. Locke GR, 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ., 3rd Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448–1456. - PubMed